Back to mobile site
Get it on Google Play

Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

October 6, 2026 4:30 PM EDT Send to a Friend
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login